講演情報
[P1-17]Construction and evaluation of novel AAV vector vaccines aimed at effective immune induction
*Ken Sugo1, Hiroshi Ueki2,3,4, Yuji Tsunekawa1, Emiko Urano5, Yukage Kobari1, Yasunari Matsuzaka1, Koji Kobiyama6, Guillermo Posadas-Herrera1, Hiromi Hayashita-Kinoh1, Mikako Wada1, Yukihiko Hirai1, Yasushi Soda1, Yasuhiro Yasutomi7,8,9, Ken J. Ishii6,10,11,12,13, Seiya Yamayoshi2,3,4, Yoshihiro Kawaoka2,3,4, Takashi Okada1 (1. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo (Japan), 2. Division of Virology, The Institute of Medical Science, The University of Tokyo (Japan), 3. Center for Global Viral Diseases, National Institute of Global Health and Medicine (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) (Japan), 5. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) (Japan), 6. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 7. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) (Japan), 8. School of Integrative and Global Majors, University of Tsukuba (Japan), 9. Department of Immunoregulation, Mie University Graduate School of Medicine (Japan), 10. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 11. Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (Japan), 12. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 13. Laboratory of Vaccine Science, Immunology Frontier Research Center, The University of Osaka (Japan))
キーワード：
Adeno-associated virus、AAV vector vaccine、SARS-CoV-2
閲覧にはパスワードが必要です
ログイン
または
コメント
コメントの閲覧・投稿にはログインが必要です。ログイン